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Azithromycin resistance levels and 
mechanisms in Escherichia coli
Cláudia Gomes1, Lidia Ruiz-Roldán  1,4, Judit Mateu  1, theresa J. ochoa2,3 & Joaquim Ruiz1
Despite azithromycin being used in some countries to treat infections caused by Gram-negative 
pathogens, no resistance breakpoint for Escherichia coli exists. the aim of this study was to analyse the 
levels and mechanisms of azithromycin resistance in E. coli. the presence of chromosomal (rplD, rplV 
and 23S rRNA) mutations, 10 macrolide resistance genes (MRGs) and efflux pump overexpression was 
determined in 343 E. coli isolates. Overall, 89 (25.9%) isolates had MICs ≥ 32 mg/L to azithromycin, 
decreasing to 42 (12.2%) when assayed in the presence of Phe-Arg-β-Napthylamide, with 35 of these 
42 possessing at least one MRG. Efflux pumps played a role in azithromycin resistance affecting the 
Minimal Inhibitory Concentration (MIC) levels of 91.2% isolates whereas chromosomal alterations seem 
to have a minimal role. At least one MRG was found in 22.7% of the isolates with mph(A) being the 
most commonly found gene. the mph(A) gene plays the main role in the development of azithromycin 
resistance and 93% of the mph(A)-carrying isolates showed a MIC of 32 mg/L. In the absence of a specific 
resistance breakpoint our results suggest a MIC of 32 mg/L to be considered in order to detect isolates 
carrying mechanisms able to confer azithromycin resistance.
Infantile diarrhoea is a serious problem in developing countries and remains the second most common cause 
of death among children under five worldwide. In fact, it causes >800,000 deaths globally per year representing 
around 10–11% of the annual global child deaths1,2. Escherichia coli play a relevant role in the death of children by 
diarrhoea, being involved in more than 120,000 deaths annually of children under 5 years old1.
The treatment approach to diarrhoea often does not require the use of antibacterial agents being frequently 
limited to the replacement of lost liquids and salts by means of Oral Rehydration Salts solutions in order to 
fight the dehydration risks3. However, according to the patient’s nutritional status, the presence of comorbidities, 
the specific pathogen, illness severity and symptom duration, the use of antimicrobial agents may be required. 
Ampicillin and cotrimoxazole are the usual first line treatments in most low and middle-income countries4,5. 
Unfortunately, antimicrobial resistance has increased over time, and in different areas these antimicrobial agents 
are losing their usefulness as a treatment of diarrhoea4–7. Since antibiotic resistance is a severe health problem 
worldwide which can lead to inefficiency of antimicrobial agents and therapeutic failure8, surveillance of the 
development of antimicrobial resistance should be performed, establishing molecular mechanisms of resistance 
to thereby design alternative treatments.
Azithromycin and other macrolides have been largely used to treat Gram-positive infections and also pos-
sess good activity against different Gram-negative microorganisms, such as Bartonella spp., Campylobacter spp., 
Haemophilus influenzae, or Neisseria gonorrhoeae9,10. Classically, macrolides present low levels of activity against 
Enterobacteriaceae which have been related to the poor membrane penetration of these antimicrobial agents, 
preventing their use to treat Enterobacteriaceae9. Nonetheless, in comparison with other macrolides, azithromy-
cin has a higher basic character9. Thus, while low permeability prevents the action of most of macrolide agents 
against Enterobacteriaceae9, this basic character confers to azithromycin a true role in the treatment of diarrhoeal 
infections related to different Enterobacteriaceae11,12. Thus, azithromycin is a promising alternative because of 
its excellent activity against most common diarrhoeagenic pathogens such as diarrhoeagenic E. coli, Shigella 
spp., Salmonella spp. or Campylobacter spp.9,10, and has been included in the considered armamentarium to fight 
against specific Enterobacteriaceae13,14.
Nonetheless, despite ranking amongst the most frequent etiological causes of diarrhoea15,16, and the asso-
ciation of some specific diarrhoeagenic pathotypes with high levels of children mortality16, at present no clin-
ical breakpoint for resistance in E. coli has been established. However, a Minimal Inhibitory Concentration 
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(MIC) ≥ 32 mg/L or a halo diameter ≤ 12 mm have been proposed as the azithromycin resistance breakpoints 
in some Enterobacteriaceae17,18. Furthermore, a series of questions on the use of azithromycin in the treatment of 
diarrhoeagenic Enterobacteriaceae remain to be fully answered. These include questions such as specific azithro-
mycin resistance rates, azithromycin resistance mechanisms in circulation, as well as a more relevant question, 
such as the effect of different alterations on the final azithromycin MIC.
Chromosomal efflux pumps are bacterial systems involved in the extrusion of molecules from bacteria to the 
environment, including bacterial products such as siderophores as well as toxics and antibiotics19. In this line 
chromosomal efflux pumps are involved in intrinsic and acquired azithromycin resistance9,20. Additionally, target 
amino acid substitutions in the L4 (rplD) and L22 (rplV) ribosomal proteins and in 23S rRNA (rrlH) have also 
been involved in macrolide resistance9.
Nonetheless, the most relevant mechanisms of azithromycin resistance in Enterobacteriaceae are those 
encoded in mobile elements9. Different Macrolide Resistance Genes (MRGs) have been described, leading to 
resistance through different pathways such as target modifications produced by rRNA methylases encoded in 
erm genes or macrolides-inactivation, mediated by esterases such as those encoded by ere(A) or ere(B) genes or 
by phosphorylases such as those encoded in the mph(A) and mph(B) genes. Additionally, transferable genes such 
as msr(A), mef(A) or mef(B) have been reported to encode macrolide-efflux pumps9.
This study aimed to evaluate the levels and the mechanisms of resistance to azithromycin in a collection of 
samples of E. coli from children with and without diarrhoea. In the absence of a specific azithromycin breakpoint 
for E. coli, we analyse the relationship between specific mechanisms of resistance and MIC levels.
Results
Antibiotic susceptibility levels. The MICs of azithromycin ranged between 0.06 mg/L and >256 mg/L, 
with a MIC50 of 8 mg/L and MIC90 of 128 mg/L (Table 1).
Overall, 140 (40.8%) and 89 isolates (25.9%) had a MIC ≥ 16 and ≥32 mg/L respectively, while only 
18.7% and 11.9% (P < 0.0001 in both cases) remained with a MIC ≥ 16 and ≥ 32 mg/L respectively when 
Phe-Arg-β-Napthylamide (PAβN) was added (Table 1, Figs 1, 2 and 3). When the analysis was made comparing 
diarrhoeagenic and commensal E. coli no differences were observed. Nonetheless, when analysing the isolates 
by pathotypes the levels of resistance of enteroaggregative (EAEC) (48.7%) and diffuse-adhering (DAEC) (45%) 
were significantly higher than those of enterotoxigenic (ETEC) (17.1%) and enteropathogenic (EPEC) (10%). 
Moreover, the resistance levels of EAEC isolates were also significantly higher than those of commensal isolates 
(P = 0.0060) (Table 1).
In the presence of PAβN all groups showed decreased levels of resistance, which was significant (P = 0.0080) 
amongst EAEC isolates (Table 1).
Effect of PAβN. In all cases the isolates were able to grow in the presence of PAβN. As mentioned above the 
addition of PAβN affected the azithromycin susceptibility levels (Tables 1, 2 and 3, Figs 1, 2 and 3). Overall, when 
the MIC was established in the presence of PAβN (MICPAβN) the effect of PAβN on the MIC levels was observed 
in 91.2% of the isolates, independently of the initial MIC (MICI) of azithromycin, with 256 being the maximum 
MICI/MICPAβN quotient (from MICI of 64 mg/L to MICPAβN of 0.25 mg/L) (Table 2). In 47 out of 89 (52.8%) 
azithromycin-resistant isolates, the addition of PAβN resulted in a MIC within the range of susceptibility (Table 1, 
Fig. 1). On the other hand, 35 out of these 47 isolates (74.5%) possessed at least 1 MRG (unidentified in one case - 
see conjugation results below).
Two commensal and 4 diarrhoeagenic isolates presented a MICI > 256 mg/L and a MICPAβN ≥ 256 mg/L, 
thereby not allowing the effect of PAβN to be accurately established.
PAβN Com. (84)
Diarrhoeagenic E. coli (259)




N 2–>256 0.06–>256 2–256 2–>256 1–>256 0.06–>256 0.06–>256
Y 0.06–>256 0.06–256 0.25–64 0.5–>256 0.25–128 0.06–>256 0.06–>256
MIC50
N 16 8 4 16 16 8 8
Y 2 1 1 2 4 1 1
MIC90
N 128 16 64 >256 128 128 128
Y 32 2 4 64 32 32 32
R (No./%)
N 23 (27.4) 12 (10.0) 7 (17.1) 38 (48.7)a 9 (45.0)b 66 (25.5) 89 (36.6)
Y 13 (15.5) 4 (3.3) 1 (2.4) 21 (26.9) 3 (15.0) 29 (10.8) 42 (12.2)
P 0.0897 0.0671 0.0571 0.0080 0.0824 <0.0001 <0.0001
Table 1. Analysis of azithromycin resistance by E. coli categories. PAβN: Phe-Arg-β-Napthylamide; Com: 
Commensal, EPEC: Enteropathogenic; ETEC: Enterotoxigenic; EAEC: Enteroaggregative; DAEC: Diffussely 
Adherent, DEC: Diarrhoeagenic; MIC: Minimal Inhibitory Concentration (expressed in mg/L); R: Resistance 
(considering MIC ≥ 32 mg/L); N: Without PAβN; Y: With PAβN; P. Differences between resistance levels in 
the absence and presence of PAβN (highlighted in bold the significant differences found). aEAEC isolates were 
significantly more resistant than commensal (P: 0.006), EPEC (P < 0.0001) and ETEC isolates (P = 0.0007). 
bDAEC isolates were significantly more resistant than EPEC (P = 0.0004) and ETEC (P = 0.0302).
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As a general rule the MICI/MICPAβN quotient ranged from 4 to 16 (267 isolates, 77.8% of total isolates). The 
MICI/MICPAβN mode was 8 (overall, and among commensal and diarrhoeagenic groups), while the mean effect 
was 12 (Table 2). When the diarrhoeagenic group was subdivided into pathotypes, only DAEC and EAEC showed 
slight differences (Tables 1 and 2).
Analysing the effect of PAβN in 255 diarrhoeagenic and 82 commensal isolates, a non-significant trend of 
a higher number of affected commensal isolates was observed (P = 0.0810). Thus, the effect of PAβN was not 
observed in 8.6% and 2.4% diarrheogenic and commensal isolates respectively. Despite the significant effect of 
PAβN on the MIC of EAEC isolates, 11 (14.7%) were not affected by PAβN. Interestingly, 10 out of these 11 iso-
lates presented MICI of 64–32 mg/L and MICPAβN of 32–16 mg/L, with MRGs being detected in only 2 cases. In 
Figure 1. Analysis of Minimal Inhibitory Concentration (MIC) of 16 and 32 mg/L to detect the presence of 
specific macrolide-resistance mechanisms. R: Resistance; RPAβN: resistance in presence of PAβN. (a) Overall. (b) 
Isolates in which no sought mechanisms of resistance was found. (c) Isolates carrying the mph(A) gene alone or 
with a target mutation. (d) Isolates carrying the mph(A) gene together other MRG. (e) Isolates carrying a MRG 
different that mph(A). (f) Isolates carrying only L4 and/or L22 amino acid changes. *The single isolate (isolate 
3491) which remains resistant after PAβN addition possesses an unidentified MRG.
Figure 2. Minimal Inhibitory Concentration (MIC) distribution. MRG: Macrolide resistance gene (other than 
mph(A)); wt: wild type. Any MIC category with ≥5% of the isolates is highlighted in dark grey. If a strain had 
a L4 and/or L22 mutation(s) and a MRG, then the isolates are included in either the mph(A) or MRG category. 
1One isolate (isolate 3491) in which an unidentified MRG was detected by conjugation.
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addition, 3 DAEC isolates (15%) were also not affected by PAβN presenting borderline significant differences with 
commensal isolates.
target mutations. Only 17 out of 263 isolates analysed (6.5%) presented mutations in the rplD or rplV 
genes. Thus, 6 isolates had mutations in the rplD gene and 7 in the rplV gene, while 4 isolates presented amino 
Figure 3. Minimal Inhibitory Concentration (MIC) cumulative curves (a) MIC cumulative curve in standard 
clinical conditions (MIC evaluation in absence of PAβN). (b) MIC cumulative curve in presence of 20 mg/L of 
PAβN. Horizontal lines marks the 50 and 90% of isolates inhibition.
E. coli 
MICI/MICPAβN (N/%)
MICI/MICPAβN ≤ 2 MICI/MICPAβN > 2
ND*0 2 4 8 16 32 64 128 256
Com (84) 2 24 29 16 7 2 1 3
DEC (259) 5 (1.9) 17 (6.6) 60 (23.2) 103 (39.8) 34 (13.1) 24 (9.3) 2 (0.8) 1 13 (5.0)
EPEC (120) 3 2 22 59 14 17 1 2
ETEC (41) 3 9 16 9 2 1 1
EAEC (78) 2 9 23 23 7 5 9
DAEC (20) 3 6 5 4 2
Overall (343) 5 19 84 132 50 31 4 1 1 16
Table 2. Analysis of MICI/MICPAβN quotient. MICI/MICPAβN = 12 (mean effect). Com: Commensal; DEC: 
Diarrhoeagenic; EPEC: Enteropathogenic; ETEC: Enterotoxigenic; EAEC: Enteroaggregative; DAEC: Diffussely 
Adherent; PAβN: Phe-Arg-β-Napthylamide; MIC: Minimal Inhibitory Concentration (expressed in mg/L); 
MICI: MIC determined in the absence of PAβN; MICPAβN: MIC determined in the presence of PAβN. ND: 
MICI > 256 mg/L. Note that in 10 out of these 16 cases the MICPAβN was <256 mg/L, and therefore the MICI/
MICPAβN quotient was >2 (e.g.: the quotient >256/128 is at least ≥4), meaning that addition of PAβN affected 
the final MIC levels. In the remaining 6 cases the possible effect of PAβN was not evaluated because we only 
were able to determine that the MICI/MICPAβN quotient was at least 2 (i.e.: the quotient >256/256 is at least ≥2, 
but not necessarily >2).
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acid codon alterations concomitantly in both genes. Thirteen of these had a MICI ≥ 32 mg/L (including 3 pre-
senting mutations in both of the targets analysed), but only one (isolate 3491), in which an unidentified MRG 
was detected by conjugation (see below), remained resistant when the MICPAβN was established. In 4 cases were 
detected concomitant MRGs (Table 4). None of the isolates analysed had mutations in the 23S rRNA gene.
Macrolide resistance genes. Seventy-eight isolates (22.7%) possessed at least one MRG (Table 5). The 
MRG most frequently found was mph(A), which was present in 53 isolates (67.9% of isolates possessing MRG) 
belonging to all the groups analysed. In 43 cases no other MRG was detected, while in the remaining 10 cases 
mph(A) was detected together with the erm(A) gene in 4 cases, the erm(B) gene in 3 cases and the mef(A) and 
ere(A) gene in 2 and 1 cases, respectively. When more than one MRG was identified within the same isolate the 
mph(A) gene was always present.
MRG were significantly more frequent among EAEC and DAEC isolates than among the remaining groups 
analysed, except when EAEC were compared with commensals. In addition, significant differences were also 
observed in the presence of MRGs among commensal and EPEC isolates (P = 0.0195) (Table 5).
PAβN
Macrolide Resistant Genes (MRGs)
Absence (265)
Presence
1 MRG (68) 2 MRGs




N 0.06–>256 8–>256 4–64 64–>256
Y 0.06–128 0.25–>256 0.25–32 16–>256
MIC50
N 8 128 8 256
Y 1 32 1 32
MIC90
N 32 >256 64 >256
Y 4 256 16 128
R (N/%)
N 81/30.6% 41/95.4%a,b 8/32% 10/100%
Y 21/7.9% 29/67.4% 4/16% 10/100%
P <0.0001 0.003 0.3209 1.000
Table 3. Analysis of azithromycin resistance in the presence and absence of macrolide resistance genes. 
PAβN: Phe-Arg-β-Naphtylamyde; MRG: Macrolide resistance gene; N: Absence of PAβN; Y: Presence of 
PAβN. MIC: Minimal Inhibitory Concentration (expressed in mg/L). R: Azithromycin resistance (considering 
MIC ≥ 32 mg/L). P: Differences in azithromycin resistance levels related to the absence or presence of PAβN, 
being significant differences highlighted in bold. aIn all cases the mph(A) gene was present together with: 
erm(A) − 4 cases; erm(B) − 3 cases; mef(A) − 2 cases; ere(A) − 1 case. bThe isolates presenting the mph(A) 
were significantly more resistant than those without MRG or presenting other MRGs (P < 0.0001).
E. coli  L4 L22 MRG
MIC ± PAβN
N Y
Commensal V52I I4L + L6Q + T72A — 16 0.125
Commensal A37S + V52L wt — 16 1
Commensal wt I4L + K6Q + T72A — 16 1
Commensal V52I + D91E + T173N wt — 16 2
Commensal wt S101T + I103L — 64 2
DAEC wt K83N + D94H + K98N mph(A) 64 4
EAEC wt V17I — 2 1
EAEC A37T + K74T wt — 4 1
EAEC V120I wt — 4 1
EAEC wt L46Q mph(A) 64 16
EAEC K123S I4L + K6Q —a >256 128
EPEC A190V wt msr(A) 8 0.5
EPEC D154E wt — 8 1
EPEC V52I + T173N I4L + K6Q + T72A mph(B) 16 4
EPEC K123S I4L + K6Q + T72A — 32 1
ETEC wt L46Q — 64 16
ETEC wt L46Q — 128 2
Table 4. L4 (rplD) and L22 (rplV) amino acid substitutions. PAβN: Phe-Arg-β-Naphtylamyde; MRG: Macrolide 
resistance gene; wt: wild type. N: Absence of PAβN; Y: Presence of PAβN. aA non-identified conjugative 
mechanism of resistance was detected (isolate 3491).
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The presence of the mph(A) gene was correlated with higher MIC levels (Table 3, Figs 1, 2 and 3), while the 
presence of other MRGs alone seemed to have a lesser effect. In fact, 40 out of 43 isolates presenting the mph(A) 
gene as a single MRG had MICs ≥ 32 mg/L. Interestingly, those isolates presenting the mph(A) gene together 
with another MRG exhibited slightly higher MIC values than those possessing only the mph(A) gene (Fig. 1). 
The effect of PAβN on the 25 isolates carrying any other MRG was significantly higher (P < 0.0001) than in those 
isolates with the mph(A) gene. Thus, only 2 erm(B), 1 ere(A) and 1 erm(A) carrying isolates were classified as 
non-wt when PAβN was added.
Conjugation assay. Transconjugants with MICs ≥ 32 mg/L were observed in 16 (24.2%) out of 66 isolates 
analysed. The mph(A) gene was transferred in 14 cases and the erm(B) gene in 3 cases (2 together with mph(A)). 
Finally, 1 transconjugant was obtained from a parental isolate (strain 125: MICI > 256 mg/L; MICPAβN = 128 mg/L, 
carrying amino acid changes in L4 [K123S] and L22 [I4L, K6Q]) in which no MRG was previously detected.
Wt/non-wt phenotypes and MIC levels. Overall, 22 out of 78 (28.2%) isolates carrying at least one MRG 
presented MIC levels < 32 mg/L. Of these, 3 isolates harbouring the mph(A) gene alone (7% of isolates carrying 
the mph(A) gene alone; 3.8% of isolates carrying MRG) and 19 carrying MRGs other than mph(A) alone (76% of 
isolates carrying other MRGs; 86.4% of isolates with MIC < 32 carrying any MRG) having a MIC < 32 mg/L. No 
isolates possessing more than one MRG presented a MIC < 32 mg/L (Figs 1 and 2). The cumulative MIC curves 
of wt isolates and those presenting a MRG other than mph(A) were similar. The cumulative MIC curves of the 
isolates possessing target mutations, mph(A) and mph(A) plus other MRG were sequentially displaced towards 
higher MIC levels. When the cumulative MICs were established in presence of PAβN the results showed that 
those belonging to wt isolates, and those presenting MRG or L4/L22 amino acid substitutions were close similar, 
with only a spurious displacement towards high MIC levels of those non-wt, while isolates possessing mph(A) 
and mph(A) plus other MRG were sequentially displaced towards higher MIC levels in a clear manner (Fig. 3).
Discussion
Diarrhoea-related deaths in children remain among the most relevant health challenges worldwide, being of spe-
cial concern in low- and middle-income countries1,2. In these countries, antibiotic therapy when needed may be 
crucial to achieve a successful outcome21,22. However, antibiotic resistance to commonly used antibacterial agents 
is dramatically increasing requiring new alternatives.
Regarding the feasibility to considered azithromycin as an alternative to treat diarrhoeagenic E. coli in the 
studied areas, the present study showed moderate azithromycin resistance levels highlighting some concerns 
about its usefulness as treatment in the absence of antibiotic susceptibility data, especially when EAEC or DAEC 
isolates are present.
In accordance with what has been previously described20,23, the relevant role of PAβN-inhibitible efflux pumps 
in azithromycin resistance has been demonstrated once more. However, differences related to the specific bacteria 
groups were observed. The presence of a series of EAEC isolates in which no PAβN-effect was observed opens the 
door to different options, including the presence of alterations in the outer membrane composition which results 
in a possible azithromycin impaired permeability leading to an increase in the basal azithromycin resistance 
levels, combined with lesser efflux pump activity, at least in regard to PAβN-inhibitible efflux pumps. Another 
possibility is the presence of different patterns of overexpressed efflux pumps. In this line, selecting azithromycin 
resistant mutants in the presence of PAβN a similar scenario was observed (MIC of 32–16 mg/L with no further 
PAβN effect). In all these mutants the presence of an overexpressed OmpW was observed24. In fact, OmpW 
has been associated with EmrE, an efflux pump belonging to the small multidrug resistance (SMR) family9,25. 
Furthermore, the overexpression of EmrE has been related to E. coli grown in the presence of erythromycin26.
In agreement with the presence of up to 7 gene copies and the subsequent need for multiple mutated alleles 
to visualize an effect on macrolide resistance9, in the present study no mutations in the 23S rRNA gene were 
E. coli  N
Phosphotransferases Methylases Esterases Efflux Pumps
Overall
Isolates Genes
mph(A) mph(B) erm(A) erm(B) erm(C) ere(A) mef(A) mef(B) msr(A) msr(D) N % N
EAEC 78 21 0 5a 3b 1 3b 3c 0 0 1 29d 39.8 37
EPEC 120 6 1 0 0 2 0 0 1 1 2 13 10.8 13
ETEC 41 2 0 0 0 1 2 0 0 1 0 6 14.6 6
DAEC 20 10 0 0 1b 0 0 0 0 0 0 10e 50.0 11
DEC 259 39 1 5 4 4 5 3 1 2 3 58 23.2 67
Comm. 84 14 0 1 2b 0 2 0 1 1 0 20f 23.8 21
Overall 343 53 1 6 6 4 7 3 2 3 3 78 23.3 89
Table 5. Macrolide resistance genes. EAEC: Enteroaggregative; EPEC: Enteropathogenic; ETEC: 
Enterotoxigenic; DAEC: Diffussely Adherent; DEC: Diarrhoeagenic; Com: Commensal. a4 of them 
concomitantly with mph(A); b1 of them concomitantly with mph(A); c2 of them concomitantly with mph(A). 
dOverall the EAEC isolates possess more MRGs than EPEC (P < 0.0001) and ETEC (P = 0.0113). eOverall the 
DAEC isolates possess more MRGs than EPEC (P < 0.0001), ETEC (P = 0.0053) and commensal (P = 0.0283). 
fOverall the commensal isolates possess more MRGs than EPEC (P = 0.019).
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observed in the 66 isolates analysed. Regarding L4 and L22, the alterations detected seem to have a minor role in 
the development of azithromycin resistance, and most might be gene polymorphisms without antibiotic resistance 
relevance. Regarding the alterations at L4 and L22 observed, to our knowledge only the alterations at amino acid 
codon K82, D94 and K98 of L22 have previously been described in in vitro obtained E. coli macrolide-resistant 
mutants but always concomitantly with other L22 amino acid alterations27. The L22 alteration L46Q was present 
in 3 cases, all having a MIC ≥ 32 mg/L. Although in one case the addition of PAβN resulted in a MIC of 2 mg/L, 
and another was concomitantly present with the mph(A) gene, a possible slight effect of this alteration on mac-
rolide susceptibility cannot be ruled out.
Regarding MRGs, in our series the relevant role of Mph(A) is undoubtable. This finding is in accordance with 
what has been previously described in E. coli and other Enterobacteriaceae9,28–31. Those isolates with the mph(A) 
gene presented the highest percentages of azithromycin resistance both in the presence and the absence of PAβN. 
Nonetheless, relevant differences were observed in the MIC levels among isolates carrying the mph(A) gene. Thus, 
while 2 mph(A)-carrying isolates had a MICI of 8 mg/L which decreased to MICPAβN of 0.25 and 1 mg/L, another 
11 isolates in which no other MRG was detected had a MICI > 256 mg/L which in no case decreased below the 
breakpoint considered in the presence of PAβN. This heterogeneity may be observed on analysing together dif-
ferent studies performed either in E. coli or other closely related Enterobacteriaceae9,28–30. Different explanations 
may be proposed, including differences related to expression levels which may be due to the number of copies of 
the gene related to its genetic environment (e.g.: plasmids with different sizes and copy numbers), with alterations 
at the promotor sequence or with the presence of other undetected MRGs.
The remaining MRGs, seemed to have a marginal role in azithromycin resistance. In fact, the cumulative MIC 
curve of these isolates was close to that of wt microorganisms. Nonetheless, those isolates presenting the mph(A) 
together with another MRG ranked among those most resistant and less affected by the addition of PAβN, sug-
gesting a slight contribution of other MRGs to final MIC levels when mph(A) gene is present. This finding was 
also showed when cumulative MICs were established.
Of these MRGs, among Enterobacteriaceae, the Msr(A) has only been described in E. coli and Enterobacter 
spp.20,32. In the present study, the msr(A) gene was detected in isolates having MICI of 8 mg/L, supporting the 
loss of activity of this gene when cloned in E. coli33. The other ATP binding transporter studied, Msr(D), it was 
detected independently of the presence of Mef(A). Moreover, in no case the mef(A) and the msr(D) genes were 
detected together. To our knowledge this is the first description of the msr(D) gene alone, since it has always 
been described concomitantly with mef(A)9. Nevertheless, the presence of polymorphisms in the mef(A) primers 
annealing region cannot be ruled out. While the effect of Msr(D) on the final MIC levels was within the range of 
those previously described, this dissociation might result in impaired Mef(A)34. Contrary to what was observed 
in the present study, Mef(A) has been described to be frequent in Enterobacteriaceae31. This difference may be 
related to the geographical origin of the samples.
This is the first description of Erm(A) in Enterobacteriaceae9,35. While no data on erm(A) functionality in 
Enterobacteriaceae has been found, previous studies have described an impairment in the expression levels of 
erm(C)36, which, if combined with a limited gene copy number, might result in a marginal influence on azith-
romycin MIC levels such as those detected in present study. Regarding Erm(B), the concomitant presence with 
mph(A) detected here in 3 isolates, has also been previously described30.
Also Ere(A) had a minimal role in the resistance to azithromycin in the present isolates. This finding is in 
accordance with the proposed lack of activity of Ere(A) in azithromycin37.
There is controversy about the ability of Mph(B) to hydrolyse azithromycin. Thus, while Chesneau and col38. 
have described its inability to confer azithromycin resistance, other authors have established a similar activity 
on hydrolysing erythromycin and azithromycin39. The only isolate of our study that possessed the mph(B) gene 
exhibited an azithromycin MIC of 16 mg/L in the absence of PAβN.
Despite this marginal role of most MRGs in the final azithromycin MIC, the detection of 6 out of 10 MRGs 
among commensal E. coli is noteworthy because of their role as a gene-reservoir40,41. Conjugation studies showed 
that only the mph(A) or erm(B) genes were transferred alone or together. Additionally, in one case in which no 
MRG was previously detected, transconjugants were obtained showing the presence of an undetermined MRG. 
In fact other MRGs have been described in E. coli9,35. However, it should be noted that the conjugation assay 
was designed to detect the transference of high levels of azithromycin resistance (>32 mg/L), and thus, if the 
resistance levels associated with transferable MRGs was lower, the transference of these elements would probably 
remain undetected.
Although the presence of non-sought mechanisms of azithromycin resistance, similar to observed in the iso-
late 3491, may not be discharged, and their presence may influences final MIC as observed when mph(A) was 
present concomitantly with other MRG. The fact that the cumulative MIC curves of those isolates presenting 
target mutations or MRG other than mph(A) were only slightly higher than those belonging to wt isolates (on 
special when role of efflux pumps was discounted with the use of PAβN) confirms the spurious or merely comple-
mentary role of these mechanisms as primary azithromycin-resistance cause in E. coli and highlight the relevant 
role of mph(A).
Thus, the present data showed that the mph(A) gene, is by far, the most effective mechanism of azithromycin 
resistance present, leading to MIC values higher than 32 mg/L in 93% of the cases, while 88.9% of isolates without 
mechanisms of resistance remained with MIC levels <32 mg/L. Therefore the use of 32 mg/L seems adequate to 
suspect the presence of mph(A) and in general of non-wt E. coli isolates. Nonetheless, the presence of sporadic E. 
coli isolates possessing Mph(A) with MIC values of 8–16 mg/L was also showed. Therefore studies are needed to 
determine the possible need for more conservative breakpoint.
In summary, the present data demonstrate the presence of azithromycin resistance among intestinal, either 
pathogenic or not, E. coli from the area of Lima, highlighting the need for susceptibility data to adequately use this 
antimicrobial agent. Moreover, the relevant and hidden role of efflux pumps in the intrinsic levels of azithromycin 
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resistance is highlighted, showing the potential clinical utility of efflux pumps inhibitors. The present data indi-
cate that the majority of isolates harbouring mph(A) will have MICs ≥ 32 mg/L. These data, combined with other 
epidemiological data will be useful to establish an E. coli ECOFF value. Clinical data will be needed to establish 
breakpoints for azithromycin in E. coli.
Materials and Methods
Bacterial strains. Three hundred forty-three diarrhoeagenic (259 isolates, including 78 EAEC, 41 ETEC, 
20 DAEC and 120 EPEC) or commensal (84 isolates) E. coli isolates from faeces samples collected in previous 
studies from children under 5 years of age in periurban areas of Lima (Peru) were recovered from frozen stocks 
to be included in the study. The uidA gene of all grown isolates was amplified as previously described by Walk and 
colleagues as a quality control42.
In all cases the previous studies in which were collected the E. coli isolates were approved by the Ethical 
Committee of the Universidad Peruana Cayetano Heredia, faeces were sampled after informed consent was 
obtained from parents and/or children legal guardians and all experiments were performed in accordance with 
relevant guidelines and regulations.
Antimicrobial susceptibility testing. The MIC of azithromycin was determined by the agar dilution 
method in accordance with the CLSI guidelines17 in the absence (MICI) and presence (MICPAβN) of 20 mg/L of 
PAβN20,41. The effect of 20 mg/L of PAβN on the viability of microorganisms was also assessed. The PAβN effect 
on the MIC levels was considered when MICI/MICPAβN > 2. The isolates with a MIC > 256 mg/L that remained 
unaltered or decreased to 256 mg/L when PAβN was added were not considered in the statistical analysis.
Ribosomal target gene amplification and DNA sequencing. In a random selected subset of 263 (rplD and 
rplV genes) and 66 samples (23S rRNA) the presence of point mutations was established by PCR (Table 6), as previously 
described23. The amplified products were recovered with Wizard SV Gel and the PCR Clean Up System (Promega, 
Madison, Wi) following the manufacturer’s instructions and thereafter sequenced (Macrogen, Seoul, Korea).
transferable azithromycin resistance mechanism detection. The presence of 10 established MRGs 
(erm(A), erm(B), erm(C), ere(A), mph(A), mph(B), msr(A), msr(D), mef(A) and mef(B) genes) was sought in all 
isolates by PCR (Table 6). In all cases negative and positive controls (microorganisms carrying the MRGs included 
in the study) were used to validate the results. Additionally random selected positive PCRs were sequenced.
Conjugation assays. A total of 66 isolates with a MIC ≥ 32 mg/L were selected to determine the transferability 
of the MRGs. The conjugation was carried out in Luria-Bertani broth (Conda, Madrid, Spain) with azide-resistant E. 
coli J53 as a recipient strain. Transconjugants were selected in plates containing 150 mg/L of sodium azide and 32 mg/L 
of azithromycin. In order to avoid considering possible contaminations the relationship of transconjugants and the 
respective recipient strain was established by REP-PCR23. The amplification of the MRGs present in the donor and 
derived transconjugant strains was performed by PCR as mentioned previously.
Target Primers Size 
(bp)
Ann. 
(°C) Ref.Gene Prot Forward (5′ → 3′) Reverse (5′ → 3′)
Macrolide Resistance Genes
ere(A) EreA GCCGGTGCTCATGAACTTGAG CGACTCTATTCGATCAGAGGC 420 60 20
erm(A) ErmA TCTAAAAAGCATGTAAAAGAAA CGATACTTTTTGTAGTCCTTC 533 52 20
erm(B) ErmB GAAAAAGTACTCAACCAAATA AGTAACGGTACTTAAATT 639 45 20
erm(C) ErmC TCAAAACATAATATAGATAAA GCTAATATTGTTTAAATCGTCAAT 642 45 20
mef(A) MefA AGTATCATTAATCACTAGTGC TTCTTCTGGTACTAAAAGTGG 345 54 20
mef(B) MefB ATGAACAGAATAAAAAATTG AAATTATCATCAACCCGGTC 1255 45 20
mph(A) MphA GTGAGGAGGAGCTTCGCGAG TGCCGCAGGACTCGGAGGTC 403 60 20
mph(B) MphB ATTAAACAAGTAATCGAGATAGC TTTGCCATCTGCTCATATTCC 868 50 20
msr(A) MsrA GCACTTATTGGGGGTAATGG GTCTATAAGTGCTCTATCGTG 384 58 20
msr(D) MsrD CCCCAGTTGGACGAAGTAA TTGTTTTTCCGATTCCATTAC 781 50 20
Macrolide Chromosomal Targets
rplD L4 GGCAAGAAAATGGCAGGTCAGATGG TTCCATCGCAGTAGACGCTTTTTCA 845 56 23
rplV L22 CGGTGGAAAGCGGAGACAAGAAGCC ACCAGTTTTGCGTCCAGTTCAGGCT 925 56 23
rrlHa — TAAGGTAGCGAAATTCCTTGTCG TGATGCGTCCACTCCGGTC 756 61 23
Other
repb — GCGCCGICATGCGGCATT — MB 40 23
uidA CATTACGGCAAAGTGTGGGTCAAT CCATCAGCACGTTATCGAATCCTT 658 55 42
Table 6. Oligonucleotids used in the study. DNA: Amplified gene or DNA fragment; Prot: Encoded protein; 
Size: Amplified product size; Ann: Annealing temperature; MB: Multiband (having different and no related 
sizes). aEncode the 23S rRNA; bPrimer designed to amplify the space between Repetitive Extragenic Palindromic 
(REP) sequences.
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statistical analysis. The Fisher exact test was used for statistical analysis. P values ≤ 0.05 were considered 
significant. A microorganism was considered “wt” when no sought mechanism of resistance other than PAβN 
inhibitable efflux pumps was identified.
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